

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1186669
<b>Application Number:</b>	10003462
<b>Confirmation Number:</b>	4354
<b>Title of Invention:</b>	Vaccine composition containing transforming growth factor alpha (TGFalpha). it use in malignant diseases therapy
<b>First Named Inventor:</b>	Aillette Mulet Sierra
<b>Customer Number:</b>	21971
<b>Filer:</b>	Jeffrey W. Guise./Norman Green (JWG/MEJ)
<b>Filer Authorized By:</b>	Jeffrey W. Guise.
<b>Attorney Docket Number:</b>	02451800002
<b>Receipt Date:</b>	05-SEP-2006
<b>Filing Date:</b>	06-DEC-2001
<b>Time Stamp:</b>	20:28:14
<b>Application Type:</b>	Utility
<b>International Application Number:</b>	

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 120
RAM confirmation Number	896
Deposit Account	232415
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:	
Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1		30797-717-201-Response.pdf	994665	yes	22
<b>Multipart Description</b>	<b>Doc Desc</b>		<b>Start</b>	<b>End</b>	
	Transmittal letter		1	1	
	Extension of Time		2	2	
	Amendment - After Non-Final Rejection		3	3	
	Claims		4	6	
	Applicant Arguments/Remarks Made in an Amendment		7	22	
	<b>Warnings:</b>				
<b>Information:</b>					
2	NPL Documents	30797-717-201-ExhibitA.pdf	791127	no	9
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	30797-717-201-ExhibitB.pdf	41230	no	1
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	30797-717-201-ExhibitC.pdf	166276	no	5
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	30797-717-201-ExhibitD.pdf	444372	no	5
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	30797-717-201-ExhibitE.pdf	1056641	no	6
<b>Warnings:</b>					
<b>Information:</b>					

7	NPL Documents	30797-717-201-ExhibitF.pdf	937442	no	5
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	30797-717-201-ExhibitG.pdf	1026030	no	10
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	30797-717-201-ExhibitH.pdf	585711	no	5
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	30797-717-201-ExhibitI.pdf	742311	no	11
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	30797-717-201-ExhibitJ.pdf	574282	no	8
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	30797-717-201-ExhibitK.pdf	240065	no	6
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	30797-717-201-ExhibitL.pdf	1026865	no	8
<b>Warnings:</b>					
<b>Information:</b>					
14	Fee Worksheet (PTO-875)	fee-info.pdf	8211	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>				8635228	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.